Stocks in the Drug Manufacturers - Major Industry

Sector: Healthcare

Drug Manufacturers - Major is an industry that produces pharmaceuticals, biologics, and medical devices. This industry is responsible for the research, development, and production of drugs and medical devices that are used to treat and prevent diseases. The industry is highly regulated and requires companies to adhere to strict safety and quality standards. Companies in this industry are typically large, multinational corporations that have the resources to invest in research and development.


Recent Signals

Date Stock Signal Type
2024-04-23 ABBV 20 DMA Resistance Bearish
2024-04-23 ABBV MACD Bullish Signal Line Cross Bullish
2024-04-23 ALIM 200 DMA Support Bullish
2024-04-23 ALIM Lower Bollinger Band Walk Weakness
2024-04-23 ALIM Narrow Range Bar Range Contraction
2024-04-23 AMGN Crossed Above 20 DMA Bullish
2024-04-23 AMGN Pocket Pivot Bullish Swing Setup
2024-04-23 AZN Stochastic Reached Overbought Strength
2024-04-23 AZN Upper Bollinger Band Walk Strength
2024-04-23 BMY Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2024-04-23 CPHI New 52 Week Closing Low Bearish
2024-04-23 CPHI New 52 Week Low Weakness
2024-04-23 CPHI Doji - Bullish? Reversal
2024-04-23 CPHI NR7-2 Range Contraction
2024-04-23 CPHI NR7 Range Contraction
2024-04-23 GILD Doji - Bearish? Reversal
2024-04-23 GILD Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2024-04-23 GILD 1,2,3 Retracement Bearish Bearish Swing Setup
2024-04-23 GILD Shooting Star Candlestick Bearish
2024-04-23 GRFS Pocket Pivot Bullish Swing Setup
2024-04-23 GRFS Stochastic Buy Signal Bullish
2024-04-23 GSK Crossed Above 20 DMA Bullish
2024-04-23 HCM Crossed Above 20 DMA Bullish
2024-04-23 JNJ MACD Bullish Signal Line Cross Bullish
2024-04-23 JNJ Cup with Handle Other
2024-04-23 LLY Stochastic Buy Signal Bullish
2024-04-23 MRK 20 DMA Resistance Bearish
2024-04-23 NVS Crossed Above 50 DMA Bullish
2024-04-23 NVS Crossed Above 200 DMA Bullish
2024-04-23 NVS Pocket Pivot Bullish Swing Setup
2024-04-23 PFE Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2024-04-23 PRPH 200 DMA Resistance Bearish
2024-04-23 PRPH Lower Bollinger Band Walk Weakness
2024-04-23 PRPH MACD Bearish Centerline Cross Bearish
2024-04-23 RMTI NR7 Range Contraction
2024-04-23 SNY Crossed Above 50 DMA Bullish
2024-04-23 SNY MACD Bullish Signal Line Cross Bullish
2024-04-23 SNY Crossed Above 20 DMA Bullish
2024-04-23 SNY Expansion Pivot Buy Setup Bullish Swing Setup

Recent News for Drug Manufacturers - Major Stocks

Date Stock Title
Apr 23 NVS FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Apr 23 BMY S&P 500 stocks with biggest estimated EPS declines for Q1
Apr 23 NVS Novartis AG (NVS) Q1 2024 Earnings Call Transcript
Apr 23 NVS Novartis Stock Jumps After Beating Expectations, Raising Guidance
Apr 23 NVS Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Apr 23 BIIB Biogen Q1 2024 Earnings Preview
Apr 23 NVS Novartis raises full-year guidance on Q1 beat, drug sales
Apr 23 NVS How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
Apr 23 BMY NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Apr 23 NVS Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results
Apr 23 SNY Sanofi succeeds in late-stage trial for blood disorder candidate
Apr 23 NVS Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Apr 23 NVS Biggest stock movers today: SPOT, GM, DHR, IBRX, NVS, and more
Apr 23 NVS Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
Apr 23 PFE Better Buy: Pfizer vs. Viking Therapeutics
Apr 23 GILD Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
Apr 23 NVS Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Apr 23 NVS The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
Apr 23 JNJ 4 Stocks to Watch on Their Recent Dividend Hikes
Apr 23 BMY Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook